# R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

> **NCT01865110** · PHASE3 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 623 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** R-CHOP
- **DRUG:** R-CHOP / R-HAD
- **DRUG:** Rituximab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01865110
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2020-11-30
- **Final completion:** 2025-01-31
- **Target enrollment:** 623 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01865110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01865110, "R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01865110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*